<DOC>
	<DOCNO>NCT02696798</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy safety ixekizumab tumor necrosis factor ( TNF ) inhibitor-experienced participant radiographic axial spondyloarthritis ( rad-axSpA ) .</brief_summary>
	<brief_title>A Study Ixekizumab ( LY2439821 ) TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<criteria>Are ambulatory . Have establish diagnosis radiographic axial spondyloarthritis ( radxSpA ) sacroiliitis define radiographically accord modify New York criterion . Participants history back pain â‰¥3 month age onset &lt; 45 year . Have prior treatment least 1 2 TNF inhibitor . Must inadequate response 2 NSAIDs therapeutic dose range total duration least 4 week OR history intolerance NSAIDs . Have history prior therapy axSpa least 12 week prior screen . Have total ankylosis spine . Have never take TNF inhibitor medication take 2 . Have recently receive live vaccine within 12 week vaccination Bacillus CalmetteGuerin ( BCG ) within past year . Have ongoing serious infection within last 12 week evidence active tuberculosis . Have compromise immune system . Have serious and/or uncontrolled disease . Have either current diagnosis recent history malignant disease . Have major surgery within 8 week baseline , require surgery study . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
</DOC>